2 reports

  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Key Therapeutic Areas

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Kolltan Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Cancer
  • Pharmaceutical
  • United States
  • Company Operations
  • Kolltan Pharmaceuticals, Inc.